GlobeNewswire·Aug 5, 2026, 4:05 PM ET

Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

AKBA

Q2 2026 net product revenues for Vafseo (vadadustat) reached $21.3 million, a 34% increase from Q1 2026.
More than 10,500 patients were active on Vafseo therapy in Q2 2026, representing a 41% increase from Q1.
The number of prescribers for Vafseo increased to approximately 1,200, a 17% rise versus Q1 2026.
Akebia initiated a Phase 2 open-label basket trial for ebribafusp to treat IgA nephropathy, lupus nephritis, and C3 glomerulopathy, with initial data expected in 2027.
Interim analysis of the VOICE trial demonstrated statistically significant improved safety outcomes for Vafseo versus ESAs regarding all-cause mortality and hospitalization.
Total company revenues were $49.1 million in Q2 2026, down from $62.5 million in Q2 2025 due to lower Auryxia sales offset by higher Vafseo sales.
Auryxia net product revenues fell to $25.5 million in Q2 2026 from $47.2 million in Q2 2025 due to generic competition.
Research and development expenses rose to $14.1 million in Q2 2026 from $11.0 million in Q2 2025, driven by clinical trial activities.
Selling, general, and administrative expenses increased to $28.2 million in Q2 2026 from $26.6 million in Q2 2025 due to commercialization activities.
Akebia reported a net loss of $8.9 million in Q2 2026 compared to a net income of $0.2 million in Q2 2025, including a $1.9 million restructuring expense.
Cash and cash equivalents stood at approximately $155.5 million as of June 30, 2026, sufficient to fund operations for at least two years.
Vafseo's intellectual property portfolio was strengthened with a new Orange Book-listed patent expiring in June 2034, extending the portfolio to 14 patents with expiration dates through 2036.
Philip J. Vickers, Ph.D., was appointed to the Board of Directors in April 2026.
Akebia plans to host a conference call on August 5, 2026, at 4:30 p.m. EDT to discuss Q2 2026 financial results.